Page last updated: 2024-12-08
thielocin a1alpha
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
thielocin A1alpha: phospholipase A2 inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 160013 |
MeSH ID | M0196894 |
Synonyms (10)
Synonym |
---|
1h-xanthene-2,7-dicarboxylic acid, 4,4a,9,9a-tetrahydro-4,4a-dihydroxy-6-methoxy-3,4,5,8,9a-pentamethyl-1-oxo-, 2-(4-((4-carboxy-3-methoxy-2,5,6-trimethylphenoxy)carbonyl)-3-methoxy-2,5,6-trimethylphenyl) 7-(4-carboxy-3-metoxy-2,5,6-trimethylphenyl) ester |
134892-23-2 |
theilocin a1alpha |
thielocin a1alpha |
thielocin a1beta |
134933-42-9 |
4-[4-[7-(4-carboxy-3-methoxy-2,5,6-trimethylphenoxy)carbonyl-4,4a-dihydroxy-6-methoxy-3,4,5,8,9a-pentamethyl-1-oxo-9h-xanthene-2-carbonyl]oxy-2-methoxy-3,5,6-trimethylbenzoyl]oxy-2-methoxy-3,5,6-trimethylbenzoic acid |
1h-xanthene-2,7-dicarboxylic acid, 4,4a,9,9a-tetrahydro-4,4a-dihydroxy-6-methoxy-3,4,5,8,9a-pentamethyl-1-oxo-, 2-(4-((4-carboxy-3-methoxy-2,5,6-trimethylphenoxy)carbonyl)-3-methoxy-2,5,6-trimethylphenyl) 7-(4-carboxy-3-methoxy-2,5,6-trimethylphenyl) este |
4-{[4-({7-[(4-carboxy-3-methoxy-2,5,6-trimethylphenoxy)carbonyl]-4,4a-dihydroxy-6-methoxy-3,4,5,8,9a-pentamethyl-1-oxo-4,4a,9,9a-tetrahydro-1h-xanthene-2-carbonyl}oxy)-2-methoxy-3,5,6-trimethylbenzoyl]oxy}-2-methoxy-3,5,6-trimethylbenzoic acid |
DTXSID70928808 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 8 (88.89) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (11.11%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (88.89%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |